InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naive disease - An International Rare Cancers Initiative (IRCI) trial
Authors
Rao, SSclafani, F
Eng, C
Guren, MG
Adams, RA
Benson, A
Sebag-Montefiore, D
Segelov, E
Bryant, A
Peckitt, C
Roy, A
Seymour, MT
Welch, J
Saunders, Mark P
Muirhead, R
Bridgewater, J
Falk, S
Glynne-Jones, R
Arnold, D
Cunningham, D
Affiliation
GI Unit, Royal Marsden Hospital NHS Foundation Trust, London, UKIssue Date
2018
Metadata
Show full item recordCitation
Rao S, Sclafani F, Eng C, Gr�nlie Guren M, Adams RA, Benson A, et al. LBA21 InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment na�ve disease - An International Rare Cancers Initiative (IRCI) trial. Annals of Oncology. 2018;29(suppl_8).Journal
Annals of OncologyDOI
10.1093/annonc/mdy424.022PubMed ID
No PMIDAdditional Links
https://dx.doi.org/10.1093/annonc/mdy424.022Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy424.022